Navigation Links
BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
Date:7/14/2011

NOVATO, Calif., July 14, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.  A Phase 1/2 trial for BMN 673 for the treatment of patients with solid tumors was initiated in January 2011 and is ongoing.

"We are excited to be at the forefront of studying the potential benefit of PARP inhibitors in hematological malignancies," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin.  "Our approach to the development of our PARP inhibitor is to identify tumor mutations that are more susceptible to treatment with BMN 673 and to target subgroups based on the genetic basis of the disease.  We are committed to the advancement of our pipeline and look forward to many clinical milestones over the next 18 months."

This Phase 1 trial is a two-arm, open-label dose escalation study to determine the maximum tolerated dose and to assess the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of once daily, oral BMN 673 in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL).  The study will enroll approximately 80 patients across multiple sites in the U.S. and UK.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMarin Announces Roll-Out of National PKU Registry
2. BioMarin to Present at the Citi Biotech Day
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
5. BioMarin Corrects Information Included in Bloomberg Article
6. BioMarin Announces Third Quarter 2008 Financial Results
7. BioMarin to Present at the Credit Suisse Healthcare Conference
8. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
9. BioMarin to Present at the Piper Jaffray Healthcare Conference
10. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
11. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, ... focused on developing therapeutics that address unmet medical ... George Elston will present at the ... Wednesday, July 8, 2015Time: , 4:45 PM EDTLocation: ... (live & archive): , www.juniperpharma.com, under  ,Investor, ...
(Date:6/30/2015)... ... June 30, 2015 , ... With its latest polyacrylonitrile (PAN) ... achieve faster flow rates in comparison to nylon or polyethersulfone (PES). Its ... allow easy liquid flow while trapping particulates as small as 0.2 micron in ...
(Date:6/30/2015)... , ... June 30, 2015 , ... Matrix Marketing ... that it has hired Gem Swartz to head up its account management department as ... director. Both Gem and Amanda bring senior account management and delivery expertise to the ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... participant in its Phase 1/2 clinical trial of ... unilateral Achilles tendinosis, has been enrolled and their ... ultrasound-guided injections. RCT-01 is comprised of non-bulbar dermal ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Matrix Marketing Group Expands Client Services Team 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... Emerging RNAi Industry through,Addition of Important and ... PALO ALTO, Calif., April 9, 2008 ... systemic RNA interference (RNAi),therapeutics, today announced that ... certain efficacy-enhancing structural elements of,small interfering RNA ...
... BOTHELL, Wash., April 9, 2008 Cardiac Science,Corporation ... advanced cardiac diagnosis,resuscitation, rehabilitation, and informatics products, announced ... Force for the initial supply,of 170 Powerheart(R) G3 ... adds to a string of international wins including ...
... Brussels: THR), a biotechnology company focused on vascular,diseases, ... has completed,patient enrolment for its Phase II MITI ... to evaluate the safety and preliminary efficacy of,microplasmin ... and twelve hours after the onset of the ...
Cached Biology Technology:Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 2Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 3Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School 4Australia Chooses Cardiac Science to Equip Its Defence Force 2Australia Chooses Cardiac Science to Equip Its Defence Force 3ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 2ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke 3
(Date:6/23/2015)... , June 22, 2015 ... the addition of the "Body-Worn Temperature Sensors ... Trends and Forecast 2014 - 2020" report ... strategic analysis of the global body-worn temperature sensors ... been segmented on the basis of types, care ...
(Date:6/18/2015)... Conn. , June 18, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market announces ... a featured segment on "Money on the Mark", scheduled to ... City June 20 th . ... will be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/17/2015)... GARDENS, Fla. , June 17, 2015 /PRNewswire/ ... solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... casual sandwich chain, to increase security, improve accountability ... fingerprint readers enable instant, non-repudiable identity confirmation for ...
Breaking Biology News(10 mins):Body-Worn Temperature Sensors Market - Global Industry Analysis 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... 2013  ImmunGene, Inc., a biotechnology company focused on developing ... it has secured $9 million in a milestone-based Series ... the Company were converted into Series A preferred stock. ... development products to IND-enabling studies. "ImmunGene, run ...
... PA, November 7, 2013 More people are cooking at ... food blogs. The photos of dishes posted on the ... value of the recipes. In addition, many food companies sponsor ... This has the potential to change the healthfulness of the ...
... of human agriculture in the Earth,s far north because ... areas of the globe scientists have studied. , Instead, ... Canada have microorganisms called cyanobacteria to mostly thank for ... provided fodder once cattle were domesticated. The process is ...
Cached Biology News:ImmunGene Raises $9 Million in Series A Financing 2ImmunGene Raises $9 Million in Series A Financing 3ImmunGene Raises $9 Million in Series A Financing 4Do food blogs serve as a source of nutritionally balanced recipes? 2Floods didn't provide nitrogen 'fix' for earliest crops in frigid North 2Floods didn't provide nitrogen 'fix' for earliest crops in frigid North 3
... and far-infrared range FT-IR spectrometers give you ... class. Yet all this comes at an ... Having a larger and faster mirror ... conventional FT-IRs provides 300%,larger solid angle of ...
... The Rapid-Screen cDNA Library Panels were designed ... three sets of PCRs to identify the ... is performed in a 96-well "Master Plate," ... 5,000 clones. Having identified the positive well(s) ...
... The Rapid-Screen cDNA Library Panels were designed ... three sets of PCRs to identify the ... is performed in a 96-well "Master Plate," ... 5,000 clones. Having identified the positive well(s) ...
... F-7000 is a research grade spectrofluorometer which ... scanning speeds of up to 60,000nm/min. ... high concentrated light beam along with low ... our FL Solutions, PC fluorescence applications software, ...
Biology Products: